Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.

Literature DB >> 26672087

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.

S Michael Rothenberg¹, Gilbert H Daniels², Lori J Wirth³.

Abstract

Entities: Chemical Disease Gene Mutation

Mesh：

Substances：

Year: 2015 PMID： 26672087 DOI： 10.1158/1078-0432.CCR-15-2298

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

1. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.

Authors: Tania Jaber; Steven G Waguespack; Maria E Cabanillas; Mohamed Elbanan; Thinh Vu; Ramona Dadu; Steven I Sherman; Moran Amit; Elmer B Santos; Mark Zafereo; Naifa L Busaidy
Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958

2. MicroRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF.

Authors: Feng Guo; Xinming Hou; Qinghui Sun
Journal: Oncol Lett Date: 2018-09-07 Impact factor: 2.967

3. Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.

Authors: Kathleen A Luckett; Jennifer R Cracchiolo; Gnana P Krishnamoorthy; Luis Javier Leandro-Garcia; James Nagarajah; Mahesh Saqcena; Rona Lester; Soo Y Im; Zhen Zhao; Scott W Lowe; Elisa de Stanchina; Eric J Sherman; Alan L Ho; Steven D Leach; Jeffrey A Knauf; James A Fagin
Journal: Endocr Relat Cancer Date: 2021-05-18 Impact factor: 5.900

Review 4. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors: David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal: Head Neck Date: 2022-03-11 Impact factor: 3.821

5. Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.

Authors: Vatche Tchekmedyian; Lara Dunn; Eric Sherman; Shrujal S Baxi; Ravinder K Grewal; Steven M Larson; Keith S Pentlow; Sofia Haque; R Michael Tuttle; Mona M Sabra; Stephanie Fish; Laura Boucai; Jamie Walters; Ronald A Ghossein; Venkatraman E Seshan; Jeffrey A Knauf; David G Pfister; James A Fagin; Alan L Ho
Journal: Thyroid Date: 2022-03 Impact factor: 6.506

Review 6. Recent advances in managing differentiated thyroid cancer.

Authors: Livia Lamartina; Giorgio Grani; Cosimo Durante; Sebastiano Filetti
Journal: F1000Res Date: 2018-01-18

7. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.

Authors: Ji Min Oh; Senthilkumar Kalimuthu; Prakash Gangadaran; Se Hwan Baek; Liya Zhu; Ho Won Lee; Ramya Lakshmi Rajendran; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal: Oncotarget Date: 2018-01-11